Xu Luo

Dr. Xu Luo

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
WLWei Lu
Wei Lu
JZJinzhong Zhang
Jinzhong Zhang
YWYungang Wu
Yungang Wu
WSWenxue Sun
Wenxue Sun
ZJZipei Jiang
Zipei Jiang
XLXu Luo
Xu Luo
Introduction: Despite the protection and management of skin has been paid more and more attention, effective countermeasures are still lacking for patients suffering from UV or chemotherapy with damaged skin. Recently, gene therapy by small interfering RNA (siRNA) has emerged as a new therapeutic strategy for skin lesions. However, siRNA therapy has not been applied to skin therapy due to lack of effective delivery vector.Methods: Here, we develop a synthetic biology strategy that integrates the exosomes with artificial genetic circuits to reprogram the adipose mesenchymal stem cell to express and assemble siRNAs into exosomes and facilitate in vivo delivery siRNAs for therapy of mouse models of skin lesions.Results: Particularly, siRNA enriched exosomes (si-ADMSC-EXOs) could be directly taken up by the skin cells to inhibit the expression of skin injury related genes. When mice with skin lesions were smeared with si-ADMSC-EXOs, the repair of lesioned skin became faster and the expression of inflammatory cytokines were decreased.Discussion: Overall, this study establishes a feasible therapeutic strategy for skin injury, which may offer an alternative to conventional biological therapies requiring two or more independent compounds.

1 January 2019 in IDCases
Verified
Journal Article
Open access
LLLinhui Li
Linhui Li
LWLingyan Wang
Lingyan Wang
CZChunhong Zhang
Chunhong Zhang
PCPeng Chen
Peng Chen
XLXu Luo
Xu Luo
Vibrio vulnificus is a serious opportunistic human pathogen, which can cause primary septicemia, wound infection and gastroenteritis. In this case, wound and blood culture failed to grow the pathogen and a next-generation sequencing method was used to detect the pathogen as V. vulnificus.

20 November 2020 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
LZLili Zhao
Lili Zhao
WLWenxi Li
Wenxi Li
XLXu Luo
Xu Luo
SSSurui Sheng
Surui Sheng

22 July 2025 in iScience
Verified
Journal Article
Open access
SZShoubin Zhan
Shoubin Zhan
YXYe Xu
Ye Xu
BLBotao Li
Botao Li
PGPeng Ge
Peng Ge
CZChunwu Zhang
Chunwu Zhang
YWYanbo Wang
Yanbo Wang
Extracellular RNAs (exRNAs) in biofluids, sourced from diverse tissues, exhibit various biological functions and diagnostic potential. Small non-coding RNAs, such as rsRNAs and tsRNAs, are abundant in tissues and likely secreted into biofluids, contributing to exRNA profiles. To comprehensively evaluate exRNAs, we employed traditional and enzymatic treatment RNA sequencing to systematically profile exRNAs across six human biofluids including serum, ascites, urine, milk, seminal plasma and saliva as well as sera from mice, rats, rabbits, and bovines. rsRNAs were identified as the most abundant exRNA species in human biofluids, with rsRNAs and tsRNAs showing high expression and species-specific profiles across animals. In serum samples from 51 healthy individuals and 69 cancer patients, exRNA-based machine learning model achieved 94.1% sensitivity and 100% specificity in cancer detection and accurately classified tumor origin. Altogether, this study reveals distinct rsRNA-abundant exRNA landscape across multiple biofluids and support the potential of exRNA signatures in pan-cancer diagnostics.

1 March 2019 in Journal of Advances in Health
Verified
Journal Article
Closed access
JHJin Hao
Jin Hao
SZSonglin Zhou
Songlin Zhou
FTFeng Tian
Feng Tian
LZLili Zhao
Lili Zhao
XLXu Luo
Xu Luo
TSTiancheng Song
Tiancheng Song
Amyotrophic lateral sclerosis (ALS) is a deadly neurodegenerative disease (NDD), characterized by the selective degeneration of both upper and lower motor circuits. To date, no therapeutic approach, either chemical or physical, would effectively cure ALS or even ameliorate the disease progression. Considering that the cells lost in ALS cannot be replaced endogenously, stem cell transplantation approaches provide promising alternatives to compensate the motor function defects. Various sources of stem cells have been employed in studies on ALS animal models as well as in clinical trials. Although the safety and feasibility of stem cell transplantation has been demonstrated in a number of reports, how to reproduce the beneficial effects for most ALS patients still remains unresolved. This review suggests several aspects that could be taken in account for further implementation of stem cell, especially neuronal lineage stem and progenitor cells, transplantation.